Publications by authors named "Flavia Colaiacovo"
Article Synopsis
- Ovarian cancer (OC) is often diagnosed late with a poor prognosis, inspiring significant research into biomarkers for early detection.* -
- Human epididymis protein 4 (HE4) is a crucial serum test for diagnosing OC and is also linked to the cancer's prognosis and recurrence.* -
- This review aims to explore HE4's role in OC processes such as proliferation, angiogenesis, and immune response, which could enhance its utility in diagnosis, prognosis, and targeted therapy.*
Article Synopsis
- - The study investigates how COVID-19 affects ovarian cancer (OC) biomarkers, focusing on CA125 and HE4 levels, finding significant HE4 increases in both OC and COVID-19 patients.
- - HE4 was elevated in 65% of OC patients and 48% of COVID-19 patients, while CA125 was elevated in 71% of OC patients and only 11% of those with COVID-19.
- - A proposed HE4 cut-off of 328 pmol/L helps differentiate between women with ovarian cancer and those with recent SARS-CoV-2 infection, indicating that HE4 remains a reliable biomarker for OC despite COVID-19 influences.
Background: The 2019 coronavirus (COVID-19) epidemic, required the development of different diagnostic tests. While reverse transcriptase real-time PCR (RT-PCR) remains the first-line test of choice in acute infection diagnosis, anti-N antibodies serological assays provide a valuable tool to differentiate natural SARS-CoV-2 immunological response from that induced by vaccination, thus the goal of our study was to evaluate three serological tests agreement for these antibodies detection.
Methods: Three anti-N different tests were examined in 74 sera from patients referred or not COVID infection: immunochromatographic rapid test (Panbio™ COVID-19 IgG/IgM Rapid Test Device Abbott, Germany), ELISA kit (NovaLisa® SARS-CoV-2 IgG and IgM NovaTech Immunodiagnostic GmbH, Germany) and ECLIA immunoassay (Elecsys® Anti-SARS-CoV-2 Roche Diagnostics, Manheim, Germany).